Radyolojik İzole Sendromda Biomarker ve Multiple Skleroza Dönüşüm

Okuda, D. T., Mowry, E. M., Beheshtian, A., Waubant, E., Baranzini, S. E., Goodin, D. S., Hauser, S. L., & Pelletier, D. (2009). Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology, 72(9), 800–805. https://doi.org/10.1212/01.wnl.0000335764.14513.1a

Okuda DT, Siva A, Kantarci O, et al; Radiologically Isolated Syndrome Consortium (RISC); Club Francophone dela Sclérose en Plaques (CFSEP). Radiologically isolated syndrome: 5-year risk for an initial clinical event.PLoS One.2014;9(3):e90509. doi:10.1371/journal.pone.009050912.

Okuda DT, Mowry EM, Cree BA, et al. Asymptomatic spinal cord lesions predict disease progression inradiologically isolated syndrome.Neurology. 2011;76(8):686-692.

Lebrun-Frénay C, Rollot F, Mondot L, et al. Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome. JAMA Netw Open. 2021;4(10):e2128271. Published 2021 Oct 1. doi:10.1001/jamanetworkopen.2021.28271

B. Yamout, M. Al Khawajah, Radiologically isolated syndrome and multiple sclerosis,Multiple Sclerosis and Related Disorders, Volume 17, 2017, Pages 234-237, ISSN 2211-0348,

Schubert, J. et al. Myelin Damage in Relapsing Multiple Sclerosis Is Associated with Decreased N-Acetylaspartate and Creatine Concentrations (P4.181). in Neurology vol. 86 P4.181 (2016).

Zhuo, Z., Li, Y., Duan, Y., Cao, G., Zheng, F., Ding, J., Tian, D., Wang, X., Wang, J., Zhang, X., Li, K., Zhou, F., Huang, M., Li, Y., Li, H., Zeng, C., Zhang, N., Sun, J., Yu, C., Han, X., … Liu, Y. (2021). Subtyping relapsing-remitting multiple sclerosis using structural MRI. Journal of neurology, 268(5), 1808–1817. https://doi.org/10.1007/s00415-020-10376-7

Salzer J, Svenningsson A and Sundstrom P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 2010; 16(3): 287–292.

Arrambide G, Espejo C, Eixarch H, et al. Neurofilament light chain level is a weak risk factor for the development of MS. Neurology 2016; 87(11): 1076–1084

Rotstein DL. Radiologically isolated syndrome and the possibility of preclinical disease activity in aquaporin-4 antibody NMOSD. Multiple Sclerosis Journal. 2022;28(4):679-680. doi:10.1177/13524585221085732

Dobson R, Ramagopalan S, Davis A, Giovannoni G. Cerebrospinal Fluid Oligoclonal Bands in Multiple Sclerosis and Clinically Isolated Syndromes: A Meta-Analysis of Prevalence, Prognosis and Effect of Latitude. J Neurol Neurosurg Psychiatry (2013) 84(8):909–14. doi: 10.1136/jnnp-2012-304695

Matute-Blanch C, Villar LM, Álvarez-Cermeño JC, Rejdak K, Evdoshenko E, Makshakov G, et al. Neurofilament Light Chain and Oligoclonal Bands are Prognostic Biomarkers in Radiologically Isolated Syndrome. Brain J Neurol (2018) 141(4):1085–93. doi: 10.1093/brain/awy021

Longbrake, E. E., Hua, L. H., Mowry, E. M., Gauthier, S. A., Alvarez, E., Cross, A. H., Pei, J., Priest, J., Raposo, C., Hafler, D. A., & Winger, R. C. (2022). The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome. Multiple sclerosis and related disorders, 68, 104143. https://doi.org/10.1016/j.msard.2022.104143

Magliozzi R, Howell OW, Nicholas R, et al. Inflammatory intrathecal profiles and cortical damage in multiple sclerosis. Ann Neurol 2018; 83(4): 739–755

Langeh, U., & Singh, S. (2021). Targeting S100B Protein as a Surrogate Biomarker and its Role in Various Neurological Disorders. Current neuropharmacology, 19(2), 265–277. https://doi.org/10.2174/1570159X18666200729100427

Mycko, M. P., & Baranzini, S. E. (2020). microRNA and exosome profiling in multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England), 26(5), 599–604. https://doi.org/10.1177/1352458519879303

Hu, W. T., Howell, J. C., Ozturk, T., Gangishetti, U., Kollhoff, A. L., Hatcher-Martin, J. M., Anderson, A. M., & Tyor, W. R. (2019). CSF Cytokines in Aging, Multiple Sclerosis, and Dementia. Frontiers in immunology, 10, 480. https://doi.org/10.3389/fimmu.2019.00480

Khademi M, Kockum I, Andersson ML, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: A suggestive prognostic marker for the disease course. Mult Scler 2011; 17(3): 335–343.)

Hedström, A. K., Olsson, T., & Alfredsson, L. (2021). The increased risk of multiple sclerosis associated with HLA-DRB1*15:01 and smoking is modified by alcohol consumption. Scientific reports, 11(1), 21237. https://doi.org/10.1038/s41598-021-00578-y

Traboulsee AL, Bernales CQ, Ross JP, Lee JD, Sadovnick AD, Vilariño-Güell C. Genetic variants in IL2RA and IL7R affect multiple sclerosis disease risk and progression. Neurogenetics. 2014 Aug;15(3):165-9. doi: 10.1007/s10048-014-0403-3. Epub 2014 Apr 26. PMID: 24770783; PMCID: PMC5094890.

Axelsson M, Malmestrom C, Nilsson S, et al. Glial fibrillary acidic protein: A potential biomarker for progression in multiple sclerosis. J Neurol 2011; 258(5): 882–888

Modvig S, Degn M, Roed H, et al. Cerebrospinal fluid levels of Chitinase 3-Like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis. Mult Scler 2015; 21(14): 1761–1770

Martinez MA, Olsson B, Bau L, et al. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis. Mult Scler 2015; 21(5): 550–561